BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 22509763)

  • 21. Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells.
    Levine PM; Lee E; Greenfield A; Bonneau R; Logan SK; Garabedian MJ; Kirshenbaum K
    ACS Chem Biol; 2012 Oct; 7(10):1693-701. PubMed ID: 22871957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
    Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
    J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.
    Wang Y; Dehigaspitiya DC; Levine PM; Profit AA; Haugbro M; Imberg-Kazdan K; Logan SK; Kirshenbaum K; Garabedian MJ
    Cancer Res; 2016 Sep; 76(17):5124-32. PubMed ID: 27488525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
    Ryu BJ; Kim N; Kim JT; Koo TS; Yoo SE; Jeong SH; Kim SH; Kang NS
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3887-90. PubMed ID: 23727044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multivalent peptidomimetic conjugates: a versatile platform for modulating androgen receptor activity.
    Levine PM; Imberg K; Garabedian MJ; Kirshenbaum K
    J Am Chem Soc; 2012 Apr; 134(16):6912-5. PubMed ID: 22509763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor as a therapeutic target.
    Gao W
    Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
    Christensen SB; Skytte DM; Denmeade SR; Dionne C; Møller JV; Nissen P; Isaacs JT
    Anticancer Agents Med Chem; 2009 Mar; 9(3):276-94. PubMed ID: 19275521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research Development, Optimization and Modifications of Anti-cancer Peptides.
    Sun ZG; Zhao LH; Yeh SM; Li ZN; Ming X
    Mini Rev Med Chem; 2021; 21(1):58-68. PubMed ID: 32767954
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.